# Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI

Study · id `cardio:ct-nct04668144` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04668144](<https://clinicaltrials.gov/study/NCT04668144>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04668144

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 359 participants.

## Technical summary

Registry record NCT04668144. Randomized; no masking; primary purpose treatment. Start 2021-02-18 (actual); primary completion 2023-02-02 (actual). Results posted on 2024-03-20.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 359 participants (enrolled count; ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Started: 2021-02-18 (actual) (ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Primary completion: 2023-02-02 (actual) (ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Completion: 2023-05-11 (actual) (ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Results first posted: 2024-03-20 (ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT04668144, source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04668144-2024-03-20`, retrieved 2026-10-26)

## The registry's words

- Brief title: Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI
- Acronym: SWAP-6
- Condition: Coronary Artery Disease
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Cangrelor
- Intervention (Drug): Prasugrel
- Lead sponsor: University of Florida
- Lead sponsor class: OTHER
- Collaborator: Scott R. MacKenzie Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Prasugrel (`cardio:prasugrel`)
- Registry lists this organization as the lead sponsor: University of Florida (`cardio:org-university-of-florida`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Switching From Cangrelor to Prasugrel in Patients Undergoing Percutaneous Coronary Intervention: The Switching Antiplatelet-6 (SWAP-6) Study (`cardio:pubmed-37609698`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1086b6989f9a3e3b54cfaefd1b123b85f88e33c2a7bcb4942db57eb48dd9ee22
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
